Trial Profile
A Randomized, Double-blind, Multicenter Phase II Trial to Compare the Immunogenicity and Safety of a Liquid-frozen and a Freeze-dried Formulation of IMVAMUNE (MVA-BN) Smallpox Vaccine in Vaccinia-naive Healthy Subjects
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Smallpox vaccine (Primary)
- Indications Smallpox
- Focus Pharmacodynamics
- Sponsors Bavarian Nordic
- 13 May 2015 Primary endpoint 'Geometric Mean Titers (GMTs) measured by ELISA' has been met, according to a Bavarian Nordic media release.
- 22 Sep 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.